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Abstract
Cervical cancer is the fourth-ranked cancer in the world and is associated with a large number of deaths annually.
Chemotherapy and radiotherapy are known as the common therapeutic approaches in the treatment of cervical
cancer, but because of their side effects and toxicity, researchers are trying to discovery alternative therapies. Beta-
glucans, a group of glucose polymers that are derived from the cell wall of fungi, bacteria, and etc. it has been
showed that beta-glucans have some anti-cancer properties which due to their impacts on adaptive and innate
immunity. Along to these impacts, these molecules could be used as drug carriers. In this regard, the application of
beta-glucans is a promising therapeutic option for the cancer prevention and treatment especially for cervical
cancer. Herein, we have summarized the therapeutic potential of beta-glucans alone or as adjuvant therapy in the
treatment of cervical cancer. Moreover, we highlighted beta-glucans as drug carriers for preventive and therapeutic
purposes.
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Introduction
Cervical cancer is known as the fourth cancer among
women and the eighth common cancer worldwide [1,
2]. Cervical cancer is a result of being infected by
some types of human papillomavirus or HPV, which
are effective on the mucosa [3, 4]. Findings indicated
that HPV is a necessary cause of cervical cancer; this
means that the other risk factors can increase the risk
of cervical cancer, but they are not able to develop
this kind of cancer in the absence of HPV [5]. In this
regard, potential cofactors involved in the cervical
cancer pathogenesis are divided into three classes: 1)
Environmental risk factors such as using hormonal
birth control [6, 7], smoking [8], parity (the number
of sex partners) [9], and have a history of being in-
fected with other sexually transmitted agents [10–12].
2) Viral risk factors including having a history of be-
ing infected with other HPV types, viral load, and in-
tegration of several viruses [13]. 3) Host risk factors
like endogenous hormones, genetic-related factors,
and generally any factor that can affect on the re-
sponse of the immune system [13].
It has been indicated that a variety of therapies could
be used in the treatment of different cancers such as cer-
vical cancer. In this word, many therapeutic approaches
i.e., surgery, chemo, and radiotherapy, utilization of im-
mune checkpoint inhibitors, therapeutic vaccines, and
antibody-drug conjugates, gene- and cell-based therapy,
and nanotechnology-based therapies could be employed
as primary lines of therapy in the cancer therapy [14–
20]. Given that some of the above approaches such as
surgery, chemo and radiotherapy, vaccine- and antibody-
based therapies have therapeutic candidates in the cer-
vical cancer therapy [21].
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Glucans are a kind of polymers that are made up of glu-
cose monomers alone and are known as a heterogeneous
class of polysaccharides. These glucose polymers are dif-
ferent from each other in some properties such as their
chain length, having branches, being alpha or beta isomers
and their ability to dissolve [22]. Beta-glucans can be
found in different plants such as oat, barley, and seaweed.
In addition, they are also involved in fungal and patho-
genic bacterial cell walls [23]. Cellulose, curdlan, lami-
narin, chrysolaminarian, lentinan, lichenin, pleuran,
zymosan, and schizophyllan are some examples of beta-
glucans (Table 1) [60]. These glucose polymers could be
linked together by β (1→ 3) linkages and provide the lin-
ear β-glycosidic chain core [61]. The glycosidic core could
provide different kinds of branches. Two important
groups of them are 1→ 4 or 1→ 6 glycosidic chains [62].
Diverse structures of beta-glucans can proceed from dif-
ferent resources. For instance, beta-glucans derived from
oat and barley are linear with large regions of beta (1, 4)
linkages separating shorter stretches of beta (1, 3) struc-
tures while beta-glucans of mushrooms have short
branches with beta (1, 6)-link coming off of the beta (1,3)
backbone. Yeast beta-glucans have beta (1, 6) branches
that are further intricate with additional beta (1, 3) re-
gions. These diversities in the beta-glucan structures
are the reason why they have different functions. The
biological functions of beta-glucans depend on their
interaction with their receptors. These interactions
are also dependent on two factors including conform-
ation of these molecules and their water solubility. It
is acknowledged that the water-soluble glucans are
more efficient [63].
Table 1 Different beta-glucans, their characteristics, sources, and potential uses
Name of beta-glucan Type Source Characteristic (s) Potential application (s) References
Cellulose Beta-1,3-glucan Plant and bacterium
(Acetobacter species)
Insoluble in water,
straight-chain, high
mechanical strength,
Wound-dressing [24–28]
Curdlan Beta-1,4-glucan Bacterium
(Agrobacterium species)
Water-insoluble,
linear, high molecular
weight, affecting
innate and adaptive
immunities, easy
modification
Immunological functions
and drug delivery
[29–33]
Laminarin Beta-1,3 and
beta-1,6-glucan
Brown algae Low molecular
weight, linear, low
viscosity, antioxidant,
and antimicrobial
activities
Development of a new
injectable system
[34–37]
Chrysolaminarian Beta-1,3-glucan Microalgae Linear, antioxidant
and immunomodulatory
capacity suitable for
immunostimulation
Development of a
new injectable
[38, 39]
Lentinan Beta-1,3 and
beta-1,6-glucan
Fungus (Shiitake) Affecting T helpers
and macrophage,
non-toxic and
well-tolerated
immunomodulator,
initiating an
inflammatory
response
Anti-tumor effects
with low side effects
[40–43]
Lichenin Beta-1,3 and
beta-1,4-glucan
Lichens
(Cetraria islandica)
Linear, non-toxic,
stimulating effects
on T cells
Being used as an
Anti-tumor agent
[44–46]
Pleuran Beta-1,3 and
beta-1,6-glucan
Fungus
(Pleurotus ostreatus)
Immunomodulatory
and anti-inflammatory
activity
Treatment of dermatitis,
being used as an anti-cancer
and anti-allergic agent
[47–51]
Zymosan Beta-1,3-glucan Yeast Anti-inflammatory
effects, affecting
dendritic and T
cells, affecting
cytokine expression
Being used as treatment for
several diseases such as cancer,
peritonitis and etc.
[52–55]
Schizophyllan Beta-1,3 and
beta-1,6-glucan
Fungus
(Athelia rolfsii)
Stimulate the
immune system,
carry metals in
water
Aid in delivering drugs
and genes, and use in
some nanofibers
[56–59]
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Some in vitro experiments have demonstrated that
large beta-glucans or some of their particular ones (like
zymosan) can cause activation of leukocytes and stimu-
late some of their activities such as phagocytosis, cyto-
toxicity, and antimicrobial actions. Intermediate or low
molecular weight beta-glucans such as glucan phos-
phate can have biological activities in vivo, but still,
their influence on cancer cells is unclear. Very short b-
glucans like laminarin are generally believed to be in-
active [64–66]. In general, some functions are attributed
to these polymers: they can have an activate macro-
phages and thereby increase the secretion of cytokines
such as interleukin 1 (IL-1), IL-6, IL-8, IL-12, and tumor
necrosis factor-α (TNF-α) and inflammatory mediators
[67]. Therefore, beta-glucans can influence on immune
defense system. Moreover, investigations on the plasma
amounts of beta-glucans showed that they can be in-
volved in the mammal’s defense mechanism against the
fungal infections [68, 69]. Apart from activating macro-
phages, T cells, and natural killer cells, and complement
can be activated by beta-glucans by the means of an al-
ternative activation pathway, as well [70]. Beside the im-
pacts of beta-glucans on immune system, beta-glucans
are able to decrease the levels of insulin, blood sugar,
and cholesterol by remaining inside the colon and intes-
tine (oat and barley beta-glucans) [60]. Recently, new
studies are have assessed the effects of these polymers
on tumor cells and they suggested that beta-glucans can
be proper candidates in the cancer therapy due to two
reasons including their anti-cancer activities and im-
mune system modulatory roles [23]. This review is an
attempt to find an answer to this question: “do beta-
glucans have any impact on cervical cancer?”
How do beta-glucans function?
The focus of recent researches has been on the inter-
action between beta-glucans and their receptors, which
are located on the cell surface, and how they allow these
polymers to affect on the cells and make some alter-
ations. Generally, glucan receptors can be expressed on
macrophages, natural killer cells and neutrophils [23],
however monocytes are the first cells in which beta-
glucan receptors were found [71]. There are four differ-
ent receptors for beta-glucans including complement re-
ceptor 3 or CR3 [72], lactosylceramide [73], selected
scavenger receptors [74], and dectin-1 (bGR) [75]. The
CR3 is a glycoprotein dimer and consists of two sub-
units: a CD18 beta chain, which is noncovalently linked
to one type of three alpha chains (which can be CD11a,
b or c). This glycoprotein is a member of the beta integ-
rin family and acts as a transmembrane glycoprotein.
CR3 is mostly found on the plasma membrane of the
phagocytic cells like neutrophils and NK cells, mono-
cytes and less on macrophages. Functions of CR3 can be
different in its resting or activated state but mediating
phagocytosis, cytotoxic reactions, and cellular adhesion
are counted as its main functions [76].
Lactosylceramide is a kind of glycosphingolipid which is
expressed on the membranes of many cells of the body.
This receptor has many functions including induction of
the inflammatory protein in the macrophages (called
MIP-2), activation of nuclear factor-κB (NF-kB), improve-
ment of oxidative stress in the neutrophils and some anti-
microbial activities. Although the real mechanisms of
these receptors are still unclear [73]. Selected scavenger
receptors are a part of predetermined pattern recognition
receptors (PRRs) that in spite of the adaptive immunity do
not identify the host products. They are involved in the in-
nate immune system and are used to recognize the micro-
organisms by their unique carbohydrates, lipids, and
proteins. Dectin-1 or beta-glucan receptor (bGR) is a type
II transmembrane protein and it is able to attach to two
kinds of glucans: β-1, 3 and β-1, 6. This receptor is mostly
expressed on cells in the innate immune system and the
main role of it is recognizing the yeast and fungi patho-
gens. The tail of this receptor consists of an immunore-
ceptor tyrosine-based activation motif (ITAM). Some
functions are found for this receptor-like including stimu-
lating the release of arachidonic acid, which is an import-
ant factor for producing some substances during the
process of acute inflammation. Moreover, it is proven that
it participates with toll-like receptor 2 and thereby induces
the pro-inflammatory response of macrophages in myco-
bacterial infections [77–80].
Beta-glucan and cancer
Beta-glucans have complicated structures and because of
that, they have several pivotal roles in human body such
as increasing resistance to infectious challenges [23],
anti-carcinogenic activities [81, 82], anti-tumor effects
[61], and activating leukocytes, T helpers, and NK cells
[83], anticoagulant effects [84], and antibiotic impacts
[85]. Generally, three kinds of study that investigated the
role of beta-glucans as a modulator for the immune
system:
1) In vitro studies: several studies have proven that
beta-glucans can act as an enhancer for macrophages
and neutrophils [86–88]. This function is possible be-
cause they can make an elevation to the production
of chemokine and pro-inflammatory cytokines and
can augment the oxidative burst [86, 89–91]. Olson
et al. [89] revealed that S. cerevisiae can affect on the
alveolar macrophages and cause an elevation in the
amounts of TNF-α production in rats. Another study
demonstrated that zymosan is able to induce the se-
cretion of TNF-α [92]. Scientists have observed that
adding the combination of soluble yeast beta-glucan
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and lipopolysaccharides (LPS), which are a part of
pathogen-associated molecular patterns, to the whole
human blood could increase the concentration of
TNF-α, IL-8, IL-10, and tissue factor (TF) [93]. Add-
itionally, these impacts are also proven for fungi,
yeast, and oat beta-glucans. Estrada et al. [94] ob-
served an augmentation in the production of IL-1a in
murine macrophages because of oat beta-glucans and
also detected an improvement in the secretion of IL-
2, IFN-gamma, and IL-4. Augmenting the activity of
leukocytes is a function of PGG or poly-[1, 6]-D-glu-
copyranosil-[1, 3]-D-glucoyranose which is extracted
from yeast. This beta-glucan makes neutrophils mi-
grate more toward C5a and it induces the stimulating
responses of the immune system with no effects on the
production of cytokines involved in inflammation [95].
Dendritic cells are a kind of antigen-presenting
cells, which Lin et al. [96] discovered the impact of
fungal beta-glucan P-SG on them. They revealed
that it results in stimulation in T helper − 1 type of
cytokine response. Furthermore, beta-glucans not
only can affect on leukocytes but they also can in-
duce epithelial cells response. For example,
pneumocystis carinii beta-glucan is able to stimulate
the alveolar epithelial cells in rats to secret macro-
phage inflammatory protein-2 [97]. Taken together,
beta-glucans modulate the response of the immune
system by cytokine secretion regulating. Another
in vitro study found that maitake mushroom beta-
glucan can induce apoptosis in prostate cancer cells
by affecting on oxidative stress. Tian et al. [98] also
revealed that beta-glucans are able to abolish the
myeloid-derived suppressor cells. Myeloid-derived
suppressor cells or MDSCs suppress the immune
system and induce tumor progression. Thus, beta-
glucans via abrogating them help the anti-tumor re-
sponses of the immune system. A report also con-
firmed the down-regulation effect of beta-glucans
on another unit that has the immunosuppressor ef-
fects on regulatory T cells (Tregs) [99].
2) Animal studies: many researchers have worked on
isolated leukocytes which are extracted from an
animal treated with beta-glucans. These studies, in
agreement with in vitro studies, has also observed
an elevation in production amounts of pro-
inflammatory cytokine [100], in oxidative burst
[101], and chemotaxis [102] and overall an induc-
tion in the specific immunity of type 1 T helpers
and also an elevated survival rate against the infec-
tion of pathogens which can be concluded from this
kind of researches [83].
3) Human studies: in spite of the numerous trials
carried out in vitro and on animals, the number of
human studies is limited. The only thing that these
studies have shown is the decreased risk of being
infected and the need for antibiotics in pre-
treatment of high-risk surgical patients [103, 104].
Another trial showed that zymosan stimulates the
regulatory antigen-presenting cells and as well, in-
creases the tolerance of the antigen-specific T cells.
Moreover, beta-glucans extracted from Candida
albicans cause an induction in the differentiation of
monocytes into dendritic cells [105].
Role of beta-glucans in monoclonal antibodies (MABs)-
associated immunotherapy
In recent years, a novel therapeutic method has been dis-
covered that is an insight for replacing chemo and radio-
therapy with large amounts of toxicity and side effects in
cancer treatment. The preference of this approach is be-
cause of its specific action that only affects the tumor cells
and therefore it minimizes the surrounding tissue injury
[23]. This new method is based on the activation of com-
plement by using monoclonal antibodies. A group of anti-
bodies which all of them are derived from the same B-
lymphocyte clone and are linked to each other is the def-
inition of this kind of antibodies or mABs [106]. Direct de-
struction of tumor cells is the result of their role as an
activator for the complement system. MABs direct the
cell-killing impressions to a tumor cell by using three
mechanisms including complement-dependent (CDC),
antibody-dependent (ADCC), and CR3-dependent cyto-
toxicity (CR3-DCC). The CR3 is one of the beta-glucans
receptors and hence, in order to be activated, it needs to
be linked into a fungal or bacterial beta-glucan. Addition-
ally, there is another ligand that binds to another site of
CR3 and is essential for activating these receptors includ-
ing iCR3b which is an antigen for tumor cells and coats
them. Nevertheless, in spite of the microorganisms, tumor
cells do not possess beta-glucans on their surface. Conse-
quently, the exogenous beta-glucans are needed to induce
this mechanism and so this method can be effective on
tumor cells adjuvant with beta-glucans [107]. Some studies
by administering beta-glucans orally [108] and intravenous
[109] have found some significant results in this field.
The impact of beta-glucans on myeloid-derived
suppressor cells
Myeloid-derived cells are a heterogeneous population.
The mononuclear type of these cells includes macro-
phages, dendritic cells, and monocytes which are termin-
ally differentiated. These cells in the case of inflammation
differentiate into macrophages and dendritic cells. MDSC
suppresses different kinds of immunity cells especially T
cells and thereby their main function is suppressing the
immune system in antigen-specific or non-specific
manners. MDSC includes two classes of cells: granulocytic
or polymorphonuclear (PMN-MDSC) and monocytic
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(M-MDSC) [110]. T reg cells, myeloid suppressor cells,
and inhibitory cytokines are three considerable compo-
nents of the immune system which cause the destruction
of anti-tumor immunity [111]. Current investigations have
informed another anti-cancer property for beta-glucans
including abrogating MDSC. Albeituni et al. [112] indi-
cated that particulate beta-glucans can corrupt both
PMN-MDSC and M-MDSC by stimulating the apoptosis
of the former and regulating the differentiation of the lat-
ter one into APC in cancer. As well, there are some other
studies confirming the part of beta-glucans are able to in-
hibit the differentiation of MDSC [113, 114]. Rui et al.
[115] considered a beta-glucan extracted from bacteria,
curdlan, and its actions against the tumor progression and
observed that curdlan is able to boost the MDSCs differ-
entiation and therefore it decreases the number of imma-
ture MDSCs. This action of curdlan results in decreasing
the suppressive impact of MDSCs against anti-tumor im-
munity. Furthermore, another group of researchers, Ning
et al. [116], worked on a beta-glucan derived from the
yeast Saccharomyces cerevisiae named WGP beta-glucan.
They found that WGP not only can activate immature
dendritic cells, T-helper 1, and differentiation of the cyto-
toxic T lymphocytes through dectin-1 signaling but it can
also abolish the immune suppression caused by tumor-
educated dendritic cells and improve priming of T cells.
Taken together, WGP is another important beta-glucan in
promoting anti-tumor immunity.
Developmental mechanisms of cervical cancer
As mentioned, the most crucial risk factor for cervical
cancer is being infected by human papillomavirus or
HPV (especially HPV 16) [117]. Till now, more than 100
types of HPV are discovered but only 40 types of them
can infect the human genital area. HPV fragments in-
clude 8000 based-pair of long circular DNAs which are
covered with a mantle of two proteins: L1 and L2. HPV
also needs six other proteins (named E1, E2, and E4-E7)
for replicating the viral DNA and the group of viral par-
ticles that are newly produced by the infected cell. Gen-
erally, HPV infects the differentiating epithelial cells of
the skin or mucosae and consequently, it’s completely
adjusted to its host and utilizes the host’s cellular mech-
anisms to achieve its own targets [13]. E6 and E7 are
two kinds of viral proteins that have essential roles in
the virus replication process [118] and so they can deter-
mine the risk of HPV types [119]. These two proteins
exert their functions via interaction with some cellular
proteins such as p53 and pRB (retinoblastoma protein, a
tumor suppressor). P53 and pRB are central molecules
for regulating the cell cycle and hence their mutation
can have important roles in the initiation and progres-
sion of various diseases such as cancer [118]. The bind-
ing of E6 to p53 provides an end to the process of
apoptosis [120] and by binding of E7 to pBR, the expres-
sion of the necessary proteins for the replication of the
DNA is stimulated [118]. Throughout the cancer pro-
gression, the integration of the host chromosome and
viral genome causes a persistent level of E6/E7 [121] and
the constant activity of E6 and E7 can augment the in-
stability of the genome, create an aggregation of onco-
gene mutations, destroy more and more the control of
cell growth, and sooner or later cause cancer (mostly
cervical cancer) [122].
Beta-glucan and cervical cancer
In our knowledge, beta-glucans have an anti-cancer property
because of their immunomodulation role on T cells and
antigen-presenting cells such as dendritic cells, macrophages,
and B lymphocytes [87, 123, 124]. As a result, beta-glucans
also might be effective in reducing cervical cancer progres-
sion through modulating both innate and adaptive immunity
[123]. Several empirical studies have been conducted in
order to investigate whether beta-glucans can be used as
novel adjuvant treatment or prognosis approaches (Table 2).
Some efforts were made in the field of cervical cancer
prevention and demonstrated that beta-glucans are also
able to affect HPV infection. Stentella et al. [142] exam-
ined the carboxymethyl β-glucan (Colpofix®) gel on a
group of people affected by CIN1. This case-control study
demonstrated that Colpofix® has an anti-cervical cancer
role in regression of CIN1. In 2010, two studies were con-
ducted on the subject of “the beta-glucans’ influence on
the HPV-correlated lesions in the genital area”. The first
study found that beta-glucans are able to treat the lesions
related to HPV infection [143] and the second study re-
vealed the efficacy of beta-glucan treatment for HPV-
CIN1 lesions [144]. These studies suggested that besides
the anti-cancer effects of beta-glucans, they also have
some effects on HPV infection, the main cause of cervical
cancer.
Most of the recent researches on beta-glucans have
been conducted on the sizofiran and its association with
cervical cancer. Sizofiran or SPG is a beta-glucan that is
derived from a mushroom called schizophyllun com-
mune Fries [145]. The therapeutic anti-cancer impacts
of sizofiran have been proven in murine and rats [146–
148]. A study shows that SPG does its function though
increasing the infiltration of T cells and Langerhans cells
(which are one kind of the antigen-presenting cells for T
cell responses) [134, 149] and so SPG can be used for
the treatment of advanced cervical cancer to prolong the
patient’s survival [133]. Nakano et al. [132] revealed that
not only infiltration of Langerhans cells or ILC enhances
T cell response also it can improve the local response to
radiation treatment in cervical cancer. Shimizu et al.
[130, 131] showed another function of SPG. They re-
vealed that sizofiran is also able to enhance the function
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of helper T cells which are located in lymph nodes of
pelvic in cervical cancer and additionally they observed
an enhanced IL-2/IL-2R system. Chen et al. [129] dis-
covered that SPG can elevate the secretion amounts of
TNF, IFN-gamma, and IL-1 from peritoneal macro-
phages and thereby affect on the cancer progression.
Furthermore, some papers are published about the usage
of SPG as adjuvant therapy in the cervical cancer treat-
ment. Hasegawa et al. [150] used a combination of
radiotherapy and SPG as a treatment for cancer of the
uterine cervix and observed that this adjuvant therapy
leads to stimulating the cytotoxic function of macro-
phages and increasing the activity of natural killer cells.
Okamura et al. [128] declared that using SPG can pro-
long the survival and recurrence time in these patients
but its influence on different stages of the cancer is the
same. Sizofiran is proven to cause a longer survival if
used in combination with radiotherapy because it is able
to develop a rapid recovery for immunologic parameters
that radiotherapy destroys [125–127].
Table 2 Functions of diverse beta-glucans and their application in cervical cancer
Beta-glucan Model (In vitro, In
vivo, Human)
Outcome (s) Application in cervical cancer
(Therapeutic / Prevention)
References
SPG Human study Promoting the recovery
of T lymphocytes and
natural killer cells
Treatment (adjuvant to
radiotherapy)
[125]
SPG Human study Increasing the survival
and recurrence time
Treatment (adjuvant to
immunotherapy)
[126]
SPG Human study stimulating a rapid
recovery of the
immunologic
parameters impaired
by radiotherapy
Treatment (adjuvant to
radiotherapy)
[127]
SPG Human study Increasing the
survival and
recurrence time
Treatment (in combination
with irradiation therapy)
[128]
SPG Human study Increasing the
number and secretion
of TNF, IL-1 and IFN-gamma
Treatment [129]
SPG Human study Augmentation helper T
(Th) cell functions of
pelvic lymph nodes
Treatment [130, 131]
SPG Human study Increasing infiltration of
Langerhans cells and
improving local response
to radiation treatment
Treatment [132]
SPG Human study Augmentation of
lymphocyte infiltration
Treatment [133]
SPG Human study Augmentation of
lymphocyte and
Langerhans cell
infiltration
Treatment [134]
Curdlan In vitro More cytotoxicity
and a broader
distribution of
loaded drug
Treatment (as drug
carrier for epirubicin)
[135]
LBE In vitro Anti-cancer effects Treatment [136]
SCG In vivo Enhancing the
hematopoietic
response, recovering
leukocyte population
in peritoneal cavity
Treatment [137]
PG101 In vivo Induces the differentiation
of progenitor cells to
granulocytes and/or
proliferation of the
committed cells
Treatment [138]
Zymosan In vivo Induction in the activity
of peritoneal macrophages
Treatment [139]
PBG In vitro Affects on both humoral
and cellular immune
response by increasing
the cytotoxic and helper
T cells and the release
of IFN-γ
Treatment and prevention [140]
Lentinan – Increasing drug efficacy Treatment (combined with
cisplatin and docetaxel)
[141]
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Curdlan is another polysaccharide in which some stud-
ies have been conducted on. It is a microbial beta-glucan
that is derived from Agrobacterium spp. and is insoluble
in water [151, 152]. Investigations showed that curdlan
can play an inhibitory role against the infection of the
AIDS virus and it also has some anti-coagulant functions
in the blood. Besides all the roles discovered for curdlan,
it appears to have low toxicity in vitro and in vivo [153,
154]. On top of that carboxymethylated curdlan or CMC
is also known for its anti-tumor effects [155–157]. As
well, Li et al. [135] synthesized cholesterol-conjugated
carboxymethyl curdlan or CCMC which is a new kind of
amphiphilic polymer and found that this polymer can be
used in cancer treatment. Entrapping epirubicin or EPB
which is a drug used in chemotherapy which in CCMC
can dissolve it, lengthen its time of retention in the cir-
culation of plasma, improve its therapeutic efficacy, and
decrease its toxicity and so it has an importance in the
cancer therapy as a novel carrier for epirubicin. Some
other studies have demonstrated that also lentinan, a
lentinula edodes-derived beta-glucan, can improve the
efficacy of chemo and radiotherapy in many cancers in-
cluding cervical cancer [158]. Ghosh et al. [136] also
worked on effects of an ethanolic extract from Lenzities
betulina named LBE on cervical cancer cell lines and ob-
served anti-cancer effects against HeLa, CaSki, and SiHa.
Roopngam and collogues investigated the Pleurotus
Sajor-caju-β-glucan polysaccharides or PBG and identified
that PBG can affect on both humoral and cellular immune
response by increasing the cytotoxic and helper T cells
and the release of the IFN-γ. Therefore it can be used as a
vaccine with HPV16E7 for the prevention and treatment
of cervical cancer [140]. A trial examined a beta-glucan
derived from edible mushroom Sparassis crispa named
SCG and found that SCG can boost the hematopoietic re-
sponses and leukocyte population in peritoneal cavity so
this beta-glucan can be a candidate for being used adju-
vant to chemotherapy but further specific researches on
cervical cancer are needed [137]. Jin et al. [138] explored
the PG101, an extracted from Lentinus lepideus, and de-
clared that this beta-glucan not only has anti-cancer ef-
fects (such as increasing proliferation of the committed
cells) also can repair the damaged bone marrows, a result
of chemo radiotherapy, and that is why it can be used as
an adjuvant with chemo and radiotherapy but still. Never-
theless, further investigations are needed to show its ef-
fects on cervical cancer. In addition, beta-glucans
extracted from yeast can have an enhancer role in the pro-
liferation of the hematopoietic cells, and it can promote
recovery of the leukocytes which are damaged because of
the sub-lethal irradiation [159]. Nikulina et al. [139] used
zymosan after treatment with actinomycin D, karminomy-
cin and bleomycin in mice and observed that zymosan
can cause an induction in the activity of peritoneal
macrophages and thus, it might have therapeutic applica-
tion in cervical cancer. Moreover, there are two alternative
approaches for cancer treatment which previously have
attracted a lot of attention including mAB-based therapy
and using MDSC suppressors. The efficacy of beta-
glucans has been significantly proven in both of these
methods and hence, beta-glucans are counted as a poten-
tial therapy in many kinds of cancer. Considering the po-
tential of both these two methods for being used generally
in cancers (exclusive of the type of cancer), they are prom-
ising therapeutic approaches for cervical cancer as well.
Nevertheless, further investigations are still needed to
prove the efficacy of these methods in cervical cancer.
Conclusions
Beta-glucans are known as immune system modulators
which they can affect on a wide range cells including T
cells, macrophages, monocytes, and antigen-presenting
cells (APCs) like dendritic cells and thereby they can im-
pact both innate and adaptive immunities. Recent stud-
ies with focusing on their influence on cytotoxic and
helper T cells, APCs, inflammatory pathways, and oxida-
tive burst (by using reactive oxygen species to destroy
cells.) have revealed that they can also have some anti-
cancer properties. Even so the main mechanisms in
which these glucans function are inducing the APCs and
T cells and thereby activating the anti-tumor immune
system and subverting the suppressors of this immune
system by stimulating the differentiation of MDSCs. It is
also worth to mention that a study represented an anti-
oxidant effect of oat beta-glucans [160] but further in-
vestigations are needed to prove their role in cancer
prevention by scavenging free radicals. Likewise, a mAB-
based therapy which is a medical progression into a new
era of cancer treatment is only effective on tumor cells
using adjuvant beta-glucans. The mentioned evidences
have shown that sizofiran, zymosan, curdlan, PBG, and
other beta-glucans can be employed in the prevention or
treatment of cervical cancer. Generally, in cancer treat-
ment, both chemo and radiotherapy have some side ef-
fects. One of the most important side effects of
chemotherapy is neutropenia. Chemotherapeutic drugs
disturb the process of the formation of the blood. Hence,
chemotherapy has negative effects on the defense system
of cancer patients and makes them susceptible to infec-
tions. Besides, radiotherapy has some side effects as well.
It also leads to hematopoietic and immune damage.
Thus, anemia, lymphocytopenia, thrombocytopenia, and
granulocytopenia are the unpleasant consequences of
radiotherapy [161]. A novel role of beta-glucans has
been discovered in recovering hematopoiesis caused by
injured bone marrow and so beta-glucans not only have
anti-cancer impressions but also can be used adjuvant to
common therapies for cancer to reduce their side effects
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in a cancer patient’s especially cervical cancer cases. Col-
lectively, beta-glucans represent a novel promising thera-
peutic way for cervical cancer.
Taken together, it seems that further investigations are
needed on beta-glucans to prove their toxicity on cer-
vical cancer cells, non-toxicity on normal cells, and their
ability for carrying drugs to the cancer site. We suggest
that some beta-glucans such as pleuran, chrysolaminar-
ian, laminarin, and zymosan which are not properly
taken into consideration in the cervical cancer therapy
field, might be convenient candidates for their character-
istics such as anti-inflammatory activities and anti-
oxidant impacts (Fig. 1). Moreover, further studies on
delivering chemotherapeutic drugs by schizophyllan and
curdlan might give new insight into cervical cancer ther-
apy. More explorations on the influence of beta-glucans
on the CR3 receptor cervical cancer cells would open
new horizons for replacing dangerous common therapies
with non-toxic treatments. In the prevention point of
view, there is a need for more researches on the mecha-
nisms by which beta-glucans influence HPV infection
and also a need for more researches on delivering HPV
proteins by beta-glucans as a vaccine.
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